Cytosorbents (CTSO) Capital Expenditures Growth (5y) (2016 - 2026)
Cytosorbents (CTSO) Capital Expenditures Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.93% |
| Dec 31, 2025 | -7.79% |
| Sep 30, 2025 | -40.60% |
| Jun 30, 2025 | -14.50% |
| Mar 31, 2025 | -61.47% |
| Dec 31, 2024 | -28.26% |
| Sep 30, 2024 | 3.76% |
| Jun 30, 2024 | -33.66% |
| Mar 31, 2024 | -31.17% |
| Dec 31, 2023 | 24.98% |
| Dec 31, 2022 | -72.84% |
| Sep 30, 2022 | 74.35% |
| Jun 30, 2022 | -38.13% |
| Mar 31, 2022 | 58.51% |
| Dec 31, 2021 | 200.54% |
| Sep 30, 2021 | -87.57% |
| Jun 30, 2021 | 66.02% |
| Mar 31, 2021 | 64.29% |
| Dec 31, 2020 | 8.60% |
| Sep 30, 2020 | 17.23% |